Medical signatory review of non-promotional scientific exchange

The classification therefore depends on purpose, content, audience, conduct and commercial context. A document can be scientifically accurate and still enter promotional territory.

The medical signatory review is the control that tests this boundary before dissemination. It is not a quality edit. It is a regulatory determination. The signatory must establish whether the proposed exchange remains objective, responsive and non-promotional, or whether it requires the controls applied to promotional material.

Defining the regulatory perimeter: LEMS versus promotional intent

Legitimate Exchange of Medical and Scientific Information, or LEMS, is relevant where a company communicates scientific information that is not intended to promote a medicine. This can occur during pipeline development, in response to a specific unsolicited enquiry, or in other controlled scientific interactions.

The classification is not determined by the absence of a sales claim. It is determined by the total communication.

A scientific exchange begins to create compliance exposure when one or more of the following conditions appears:

• The medicine is presented in a way that supports prescribing, recommendation or commercial uptake.
• The communication goes beyond the specific scientific question or request.
• The material uses selective evidence, comparative framing or benefit emphasis without a balanced account of limitations.
• The audience, setting or invitation indicates a commercial objective.
• The company’s medicine is introduced into an educational meeting without a clear scientific necessity.
• The communication contains information that could be understood as an inducement or product positioning.
• The process allows the material to be distributed proactively rather than in response to a defined scientific need.

The relevant test is therefore functional. The same study summary may be acceptable in one setting and promotional in another. A response to a narrowly framed unsolicited enquiry has a different compliance profile from a slide deck distributed to a broad audience. A pipeline briefing has a different profile from a branded company meeting.

The ABPI Code permits LEMS during product development provided the exchange does not constitute promotion. That condition is decisive. Development status does not neutralise promotional intent. An investigational compound, a pre-launch product or a medicine outside the relevant promotional scope can still be presented in a manner that creates regulatory risk.

Scientific accuracy is necessary. It is not sufficient. The controlling question is whether the communication performs a promotional function.

A five-part classification sequence

A practical review should proceed through a fixed sequence. The sequence reduces interpretive variance between medical, regulatory, legal and commercial reviewers.

1. Identify the initiating event.

The review should record whether the material was created for a documented unsolicited enquiry, a planned scientific exchange, a conference interaction, an internal briefing or an organised external meeting. The origin of the communication establishes the first boundary.

2. Define the scientific question.

The enquiry or exchange should be reduced to its actual subject. This may concern mechanism of action, study methodology, safety data, epidemiology or another scientific issue. A broad question creates more scope for uncontrolled content. A specific question creates a measurable response perimeter.

3. Map every product reference.

Product name, brand assets, mechanism, indication, dosage, efficacy, safety, comparative data and development status should be assessed individually. The presence of a company medicine is not automatically determinative, but it increases the need for disciplined review.

4. Assess the communication pathway.

The reviewer should establish who requested the information, who will receive it, whether the material will be archived, whether it can be forwarded and whether a field or commercial function has influence over distribution. A response that is scientifically acceptable in isolation may become promotional through its distribution model.

5. Determine the applicable control.

The output should be a documented classification: non-promotional scientific exchange, promotional material requiring the relevant certification and examination process, or communication requiring escalation because the facts are unresolved.

This sequence should produce an auditable rationale. A signatory should not be required to infer the purpose of a document from the document alone. The request, audience, proposed use and distribution method form part of the evidence.

The signatory mandate: qualifications and PMCPA registration

The final medical signatory has a defined regulatory status. In the UK, the final signatory must be one of the following:

• A medical practitioner registered in the UK.
• A pharmacist registered in the UK.
• For dental products only, a dentist registered in the UK.

The individual must be employed or retained by the pharmaceutical company. The role cannot be assigned informally to an unqualified reviewer because the material is described as scientific rather than promotional.

Companies that are ABPI members, and non-members that voluntarily accept PMCPA jurisdiction, must officially register nominated signatories with the PMCPA under the relevant Clause 8 requirements. Registration is not an administrative detail that can be resolved after approval. It establishes whether the person is authorised to perform the required signatory function within the company’s compliance framework.

The review record should therefore identify:

• The nominated signatory.
• The professional registration basis.
• The company relationship or retention arrangement.
• The date and version of the material reviewed.
• The intended audience and distribution channel.
• The classification decision.
• The rationale for treating the exchange as non-promotional.
• Any limitations imposed on use or dissemination.
• Escalation decisions and unresolved issues.

A signature without a defensible record is weak mitigation. The formal act of approval does not correct an incomplete classification. It merely attaches a qualified person to it.

Signatory review is not scientific peer review

Scientific peer review examines whether the data have been represented accurately and whether the interpretation is methodologically defensible. Medical signatory review addresses a broader risk perimeter.

The signatory must examine:

This distinction prevents a recurrent error: treating scientific validity as proof of non-promotional status. The evidence may be valid. The communication may still be non-compliant.

Operationalising the workflow: where AQPs assist and where they do not

The ABPI Code allows Appropriately Qualified Persons, or AQPs, to assist with copy approval workflows. Their use can reduce the operational burden placed on medical signatories, particularly where the principal task is controlled verification rather than substantive medical judgement.

An AQP may assist with activities such as checking final printed materials against approved electronic masters. This is a production-control function. It can confirm that the final output has not changed from the approved version through typesetting, formatting or printing.

The distinction between assistance and final accountability must remain explicit. An AQP does not become a substitute for the qualified final medical signatory merely because the document contains scientific information. The signatory must retain oversight of the classification and substantive review.

A controlled workflow should separate the stages:

1. Intake and triage

The request is logged with its origin, scientific subject, recipient, proposed timing and intended channel.

2. Regulatory classification

The responsible review team determines whether the proposed communication is promotional, non-promotional or unresolved. The decision is based on purpose and context, not the document title.

3. Scientific and medical assessment

Claims, references, safety information, limitations and interpretation are examined. Any data that cannot be supported should be removed, qualified or escalated.

4. Signatory determination

The qualified signatory confirms the classification and assesses whether the exchange can proceed under the proposed controls.

5. AQP production verification

Where applicable, an AQP checks the final output against the approved master. This prevents post-approval variance.

6. Controlled release

The material is issued only to the defined audience and through the approved channel. Distribution outside that perimeter requires a new assessment.

7. Retention and monitoring

The request, final material, approval record, distribution evidence and subsequent amendments are retained according to the company’s applicable procedures.

The most material control weakness is often found after approval. A document may be correctly reviewed, then altered by a local team, reformatted for a meeting or forwarded to recipients outside the original scope. Each change introduces variance. The control environment must therefore monitor use, not merely certify creation.

The 2019 introduction of AQPs into the ABPI Code framework recognised the need to allocate certain operational tasks without collapsing the distinction between production verification and final medical accountability. That distinction remains central.

Reactive enquiries: specificity is the control

Pre-drafted standard medical responses can be reviewed in advance. They can be dispatched only when they directly and solely relate to a specific incoming request and do not appear promotional.

This requirement creates a narrow operating model. A standard response is not a standing permission to distribute a scientific message whenever a related topic arises. The incoming request must support the content sent. If the request changes, the response must be reassessed.

The response process should capture the following elements:

• The exact question received.
• The identity and professional status of the enquirer, where relevant to the response.
• The date and channel of receipt.
• The approved response version.
• The scientific and regulatory rationale for the response.
• Any information excluded because it exceeded the request.
• The final recipient and transmission method.
• Any follow-up communication.

A response becomes higher risk when it contains additional product information that was not required to answer the enquiry. The expansion may be small: an efficacy result, a comparative statement, a treatment positioning point or a reference to an adjacent indication. The regulatory effect is not measured by word count. It is measured by function.

The reviewer should also assess whether the response is genuinely reactive. A pre-drafted answer prepared for anticipated questions may be permissible within a controlled process, but the actual dispatch must remain linked to the specific unsolicited request. A commercial team cannot convert a reactive response into a proactive campaign by collecting similar questions and distributing the same document to a selected audience.

The response perimeter

A defensible response has a defined perimeter:

• It answers the question asked.
• It uses evidence relevant to that question.
• It does not add unnecessary product positioning.
• It does not include promotional calls to action.
• It does not create a broader narrative about the medicine.
• It is transmitted only to the requesting recipient unless separately assessed.
• It remains consistent with the approved version.

If the response cannot satisfy these conditions, escalation is required. The correct mitigation may be a narrower response, a revised communication pathway or treatment as promotional material. The label applied by the author is not determinative.

Educational meetings and the commercial context

Educational meetings present a recurrent classification failure. A meeting may be described as medical education, scientific exchange or professional development. The designation does not control the outcome.

Where a company-organised educational meeting mentions the company’s medicine directly or indirectly, PMCPA guidance indicates that the meeting is likely to be viewed as promotional because of the commercial interest. That likelihood creates a clear compliance implication: full promotional compliance controls may be necessary.

The indirect reference is material. A medicine need not be the sole subject of the agenda. It may enter through:

• A disease-area presentation structured around the company’s product.
• A case discussion that directs attention toward the product’s use.
• An invited speaker’s slides containing product-linked content.
• A programme title, invitation or learning objective that positions the medicine.
• A question session managed in a way that produces product-specific discussion.
• Distribution of branded or product-specific materials during the event.

A medical signatory review should therefore examine the complete event architecture, not only the scientific slides. The invitation, agenda, speaker brief, venue materials, registration pathway, audience selection and post-event follow-up can all alter the classification.

The ABPI Code provisions concerning meetings and educational support, including Clauses 10.4 and 12, form part of the relevant control perimeter. The July 2025 PMCPA Q&As on non-promotional medical educational meetings add current interpretive context. The prudent approach is not to rely on the meeting title. It is to assess commercial interest and practical effect.

A meeting that is genuinely independent may have a different risk profile from a company-organised event. However, independence must be demonstrated through governance and conduct. A nominally educational format does not neutralise company influence.

The meeting format is not the classification. The commercial context is.

Pipeline communications and pre-authorisation risk

Pipeline communications create a specific form of regulatory exposure. Development-stage information may fall within legitimate scientific exchange, but the content must remain non-promotional. The absence of a marketed indication does not remove the need for review.

The medical signatory should assess:

1. Development status

The material should identify the relevant stage of development without implying availability, recommendation or established clinical utility beyond the evidence.

2. Evidence maturity

Early findings must not be presented with the certainty associated with established clinical evidence. Interim, exploratory or limited data require precise qualification.

3. Uncertainty and limitations

Study design, population, endpoint status, sample limitations and unresolved safety questions should be represented in proportion to their relevance.

4. Audience competence

The recipient must be appropriate for the level and nature of the information. Technical detail does not itself make a communication non-promotional.

5. Commercial framing

Investment, competitive positioning, anticipated market value or treatment preference can alter the purpose of an otherwise scientific exchange.

6. Forwardability

Materials should be designed and distributed on the assumption that uncontrolled forwarding may occur. The original context should not be the only protection.

7. Territorial scope

A UK-compliant process does not automatically establish compliance in another jurisdiction. Local requirements may differ, particularly where promotional definitions and pre-authorisation controls are not aligned.

The review should distinguish factual scientific disclosure from strategic positioning. Both may use the same data. Their regulatory significance depends on why the information is being communicated and how the recipient is expected to act on it.

Escalation thresholds

The material should be escalated when the classification depends on assumptions that are not recorded. Examples include:

• Uncertainty about whether the enquiry was unsolicited.
• Uncertainty about whether the audience was selected for commercial reasons.
• A request to add product information not necessary to answer the question.
• A meeting in which the company’s medicine will be mentioned despite an educational label.
• A proposed distribution channel broader than the original scientific interaction.
• Changes to approved content after signatory review.
• Use of a non-registered or otherwise inappropriate person for final certification.
• Inconsistency between the approved master and the version intended for release.

Escalation is not a failure of workflow. It is a mitigation response to unresolved variance. The failure occurs when uncertainty is concealed by a generic classification or a routine signature.

Building a defensible audit trail

A regulator or self-regulatory body will assess the communication as it occurred, not as it was intended internally. The company therefore needs evidence that connects the request, review, approval and use.

The audit trail should be capable of answering five questions:

• What was communicated?
• Why was it communicated?
• To whom was it communicated?
• Who approved the communication?
• Was the approved version used within the approved perimeter?

A file containing only the final document and a signature is insufficient for higher-risk exchanges. The rationale should be visible. The record should show the question received, the classification logic, the decision-maker’s qualifications, the restrictions on use and the final distribution.

Monitoring should also examine operational behaviour. Useful indicators include:

• The proportion of reactive responses issued without a linked enquiry.
• Repeated use of a standard response outside its approved scope.
• Unapproved edits to signatory-reviewed materials.
• Distribution to recipients not included in the original assessment.
• Educational meetings where product-specific content appears after approval.
• Delayed registration or changes in nominated signatory status.
• Recurring escalation themes that indicate a defective procedure.

These indicators create quantifiable evidence of control performance. They also expose variance between written procedures and actual practice.

The 20MB maximum file upload limit for the PMCPA Nominated Signatories Form is an administrative parameter, not a substantive compliance standard. It illustrates a broader point: operational details must be controlled, but they must not be confused with the legal or self-regulatory basis for signatory authority.

The final risk assessment

Medical signatory review of non-promotional scientific exchange is a boundary-control function. It determines whether scientific content remains within a legitimate exchange or acquires promotional effect through purpose, context, audience or distribution.

The ABPI Code permits LEMS during product development when the exchange does not constitute promotion. Final review in the UK requires an appropriately qualified and registered medical practitioner, pharmacist or, for dental products, dentist. Companies within the PMCPA framework must register nominated signatories. AQPs can support controlled copy approval tasks, but they do not erase the distinction between operational assistance and qualified final accountability. Reactive responses must remain directly and solely connected to specific unsolicited enquiries. Company-organised educational meetings involving the company’s medicine are likely to require promotional controls.

The decisive control is not terminology. It is documented causality: the request led to the content, the content remained within scope, the qualified signatory assessed the risk, the approved version was used, and distribution remained controlled.

Where those links are absent, the classification is unstable. The resulting exposure is not theoretical. It is a foreseeable compliance variance that a later complaint, audit or PMCPA examination can reconstruct from the record.